약물감시 자동화 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pharmacovigilance automation market size is projected to be USD 2.67 billion in 2025, USD 3.03 billion in 2026, and reach USD 5.68 billion by 2031, growing at a CAGR of 13.42% from 2026 to 2031.

This report is Segmented by Component (Software and Services), Technology (Artificial Intelligence & Machine Learning, and More), Functionality (Automated Case Processing, and More), Deployment Mode (Cloud-Based, On-Premise, and Hybrid), End User (Pharmaceutical Companies, and More), and Geography (North America, Europe, and More). The Market and Forecasted in Terms of Value (USD).

Global Pharmacovigilance Automation Market Trends and Insights

Rising Regulatory Pressure for Drug-Safety Compliance

Global regulators have shortened reporting timelines and tightened data-quality thresholds, forcing sponsors to automate validation checks that human teams cannot repeat at scale. The FDA and EMA issued joint principles in January 2026 that treat algorithmic duplicate detection, narrative summarization, and causality coding as medical-device functions, requiring pre-market validation and post-market surveillance. EMA pilots that began in September 2025 across 12 marketing-authorization holders are already highlighting compliance gaps in legacy systems. These mandates reward vendors whose platforms ship with audit trails, version control, and ISO 13485 certification, thereby lifting the pharmacovigilance automation market. CIOMS reinforced the trend in December 2025 by recommending that AI model training datasets and bias-mitigation steps appear in periodic safety reports. Collectively, these measures accelerate investment while increasing entry barriers for solutions without embedded compliance tooling.

Increasing AE-Data Volumes From Multi-Channel Sources

Adverse-event counts are exploding as reports move beyond physician submissions to include mobile apps, social media, and wearables. India logged 4.8 million cases in 2024 via its mobile reporting app, nearly doubling 2020 figures. Academic work shows 40% of social-media events never reach formal reporting systems, yet 15% surface sooner when mined algorithmically. Decentralized trials feed electronic patient-reported outcomes that regulators expect sponsors to screen within 24 hours, an unrealistic task for manual reviewers. Europe's DARWIN EU network will add 150 million electronic records by 2027, overwhelming traditional safety desks. Automated ingestion and NLP triage, therefore, become essential, further expanding the pharmacovigilance automation market.

Data-Privacy & Cross-Jurisdiction Compliance Hurdles

The EU's GDPR blocks data transfers to non-adequate jurisdictions unless complex safeguards exist, complicating cloud deployments headquartered in the United States. China's PIPL enforces strict localization, obliging multinationals to run isolated databases inside the country. The FDA still requires 21 CFR Part 11 compliance for outsourced hosting, adding audit overhead for small sponsors. These overlapping statutes fragment data lakes, inflate validation costs, and slow the migration pace, limiting near-term addressable revenue for the pharmacovigilance automation market.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Adoption of AI/ML-Centric Safety Platforms
2. Cost-To-Serve Reduction Mandates by Big Pharma
3. Legacy Safety-Database Integration Complexity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Services are winning share even as software retains a dominant revenue base. In 2025, software captured 65.82% of the pharmacovigilance automation market share. Growth tilts toward managed offerings, however, with services posting a 14.31% CAGR to 2031 on the back of per-case outsourcing contracts that wrap technology, labor, and regulatory submissions into a single invoice. EVERSANA's July 2025 launch of ORCHESTRATE PV epitomizes this pivot by letting mid-tier biotechs bypass licenses altogether.

Adoption of hybrid engagement models is also fostering service revenue. Sponsors lean on consultants for 12-18 month migrations that demand data mapping, validation scripting, and regulator-facing documentation. Niche firms such as Nextrove specialize in multilingual case translation, addressing the restraints outlined earlier. Over the horizon, deeper automation could cannibalize human services, but complexities tied to cell-and-gene follow-up and real-world-evidence ingestion suggest sustained room for blended tech-plus-people packages inside the pharmacovigilance automation industry.

Artificial intelligence and machine learning are expected to account for 45.17% of deployments in 2025. Meanwhile, NLP is experiencing the fastest growth, with a 15.92% CAGR, fueled by the adoption of decentralized trial narratives, patient-reported outcomes, and analysis of social media data. Transformer architectures deliver an impressive 92% extraction accuracy for English, significantly outperforming traditional rule-based systems.

Vendors are pouring R&D into multilingual corpora to narrow the bias gap flagged as a restraint. Robotic process automation remains foundational but is flattening as capabilities embed directly into broader suites. Early pilots involving blockchain audit trails and graph-database signal maps are tucked in the "Others" bucket, signaling future adjacency plays rather than near-term revenue swings for the pharmacovigilance automation market.

Geography Analysis

North America generated 36.48% of 2025 revenue due to the FDA's aggressive enforcement and early AI uptake. Form 483 observations tied to safety deficiencies jumped 23% in 2024, pushing sponsors toward automated duplicate checking and narrative summarization. The January 2026 FDA-EMA AI principles further embolden investment by clarifying validation expectations. Canada and Mexico, though smaller, benefit from USMCA alignment that encourages centralized case-intake hubs. Integration headaches with entrenched Argus databases slow cloud conversions, sustaining a parallel demand stream for service consultants inside the pharmacovigilance automation market.

Europe ranks second in revenue and benefits from EMA initiatives such as DARWIN EU and the Pharmacovigilance Risk Assessment Committee's 2026 compliance-monitoring pilots. Germany, the United Kingdom, France, Italy, and Spain host dense pharma clusters driving license activity. GDPR's tough stance shapes deployment choices, explaining why hybrid architectures grow quickly. Recent ICH updates dovetail with European e-submission gateways, reducing customization overhead for vendors and making the region an attractive early-mover playground for the pharmacovigilance automation market.

Asia-Pacific is the fastest mover with a 19.34% CAGR through 2031, encouraged by China's 2024 e-submission mandate and India's mobile-app surge. Japan's MIHARI demonstrates tangible ROI by catching signals six months earlier, inspiring copycats in South Korea and Australia. Localization rules like China's PIPL foster domestic-cloud partnerships with Alibaba and Tencent, spawning a region-specific ecosystem inside the broader pharmacovigilance automation market. Middle East, Africa, and South America remain nascent but could accelerate post-2028 as GCC regulators build digital infrastructure and Latin American countries harmonize with ICH standards.

1. AB Cube
2. Accenture
3. Aris Global
4. BioClinica (Clario)
5. Capgemini
6. Cognizant
7. Ennov
8. EXTEDO
9. Genpact
10. IBM
11. IQVIA
12. Kinapse (Syneos Health)
13. Oracle
14. Parexel International
15. ProductLife Group
16. RxLogix
17. Sparta Systems (Honeywell)
18. TCS
19. United BioSource (UBC)
20. Veeva Systems
21. Wipro

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Regulatory Pressure for Drug-Safety Compliance
  • 4.2.2 Increasing AE-Data Volumes From Multi-Channel Sources
  • 4.2.3 Rapid Adoption of AI/ML-Centric Safety Platforms
  • 4.2.4 Cost-To-Serve Reduction Mandates by Big Pharma
  • 4.2.5 Automation Demand from Cell & Gene Therapy Post-Marketing Surveillance
  • 4.2.6 Expansion of Real-World-Data (RWD) Networks Enabling Continuous Signal Detection
• 4.3 Market Restraints
  • 4.3.1 Data-Privacy & Cross-Jurisdiction Compliance Hurdles
  • 4.3.2 Legacy Safety-Database Integration Complexity
  • 4.3.3 Vendor-Lock-in Concerns due to Proprietary AI Models
  • 4.3.4 Multilingual NLP Model Bias Affecting Case-Intake Quality
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Component
  • 5.1.1 Software
  • 5.1.2 Services
• 5.2 By Technology
  • 5.2.1 Artificial Intelligence (AI) & Machine Learning (ML)
  • 5.2.2 Natural Language Processing (NLP)
  • 5.2.3 Robotic Process Automation (RPA)
  • 5.2.4 Others
• 5.3 By Functionality
  • 5.3.1 Automated Case Processing
  • 5.3.2 Adverse Event Reporting
  • 5.3.3 Signal Detection & Risk Management
  • 5.3.4 Medical Literature Monitoring
  • 5.3.5 Others
• 5.4 By Deployment Mode
  • 5.4.1 Cloud-based
  • 5.4.2 On-premise
  • 5.4.3 Hybrid
• 5.5 By End User
  • 5.5.1 Pharmaceutical Companies
  • 5.5.2 Biotechnology Companies
  • 5.5.3 Contract Research Organizations (CROs)
  • 5.5.4 Others
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
  • 6.3.1 AB Cube
  • 6.3.2 Accenture
  • 6.3.3 ArisGlobal
  • 6.3.4 BioClinica (Clario)
  • 6.3.5 Capgemini
  • 6.3.6 Cognizant
  • 6.3.7 Ennov
  • 6.3.8 EXTEDO
  • 6.3.9 Genpact
  • 6.3.10 IBM Watson Health
  • 6.3.11 IQVIA
  • 6.3.12 Kinapse (Syneos Health)
  • 6.3.13 Oracle Corporation
  • 6.3.14 Parexel International
  • 6.3.15 ProductLife Group
  • 6.3.16 RxLogix
  • 6.3.17 Sparta Systems (Honeywell)
  • 6.3.18 TCS
  • 6.3.19 United BioSource (UBC)
  • 6.3.20 Veeva Systems
  • 6.3.21 Wipro

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment